FDA warns about use of certain glucose monitoring strips

Share this article:

The Food and Drug Administration Friday issued a public health notification regarding certain glucose monitoring strips.

It said that healthcare practitioners should not use GDH-PQQ (glucose dehydrogenase pyrroloquinoline quinine ) test strips on patients receiving therapeutic products containing non-glucose sugars. These sugars can falsely elevate glucose results, which may mask hypoglycemia or prompt excessive insulin administration, leading to a serious injury or death, the FDA said. Patients with serious medical conditions, including kidney failure and rheumatoid arthritis are most likely to use these therapies. Diabetics use glucose monitoring strips to test their blood sugar levels.

Other glucose test strips do not react harmfully with the non-glucose sugars, the FDA noted. The unaffected methods are glucose oxidase, glucose dehydrogenase nicotine adenine dinucleotide (GDH-NAD) or glucose dehydrogenase flavin adenine dinucleotide (GDH-FAD).

For more, click here.

 


Share this article:

More in News

Nursing home antipsychotic use has dipped nearly 19% under national effort, latest figures show

Nursing home antipsychotic use has dipped nearly 19% ...

The percent of long-stay nursing home residents receiving antipsychotic medication has decreased 18.8% under a nationwide initiative that started in 2012.

Jimmo succeeds in getting Medicare coverage, two years after landmark case ended

Glenda Jimmo has reached a settlement with the federal government and will finally receive Medicare coverage for claims that were denied in 2007, which led her to file a class-action lawsuit over the so-called "improvement standard."

Breier named new CEO at Kindred

Breier named new CEO at Kindred

Kindred Healthcare announced Thursday that it has chosen a new top executive to lead its push toward creating a mammoth national brand. Benjamin A. Breier, the company's current president and ...